Question posed by non-Oncologist P&T member: “Are mutations in oncology mutually exclusive”?
P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
© 2024 MMIT